Summary
A Phase I trial of pirarubicin (4′-O-tetrahydropyranyl-doxorubicin) was undertaken to study its toxicity and to gain preliminary knowledge of its efficacy. The dose was escalated by increments of 10 from 30 to 70 mg/m2. Out of 20 patients, 19 were evaluable for toxicity and response to treatment. Hematologic toxicity was dose limiting and dose related. Other adverse effects included nausea and vomiting, hair loss, and stomatitis. No acute cardiotoxicity was encountered. In 2 patients with metastatic breast cancer who had not been pretreated with cytostatic agents, a partial remission was achieved lasting for 5 months. In 6 patients, tumor parameters did not change for a median of 3 months, and 11 patients suffered progressive disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dantchev D, Paintrand M, Hayat M, Bourut C, Mathé G (1979) Low heart and skin toxicity of tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot 32:1085–1086
Majima H (1983) Exploratory clinical study of 4′-O-tetrahydropyranyl doxorubicin (THP-ADM), Phase I. Gan To Kagaku Ryoho 10:134–140
Majima H (1983) Preliminary Phase II clinical study of 4′-O-tetrahydropyranyl doxorubicin (THP-ADM). Gan To Kagaku Ryoho 10:805–810
Mandell GL, Sande MA (1985) Antimicrobial agents. In: Gilman AG, Goodman LS, Rall TW,, Murad F (eds) The pharmacological basis of therapeutics 7th edn. Macmillan, New York, pp 1199–1202
Mathé G, Umezawa H, Tapiero H, Machover D, de Vassal F, Misset JL, Ribaud P, Musset M, Eriguchi M (1985) Oriented Phase II trial in advanced breast cancer of 4′-O-tetrahydropyranyl-adriamycin (THP-ADM), a non hair, non heart toxic anthracycline. Proc Am Soc Clin Oncol 4:71
Nakada H, Ogawa M, Miyamoto H, Inagaki J, Horikoshi N, Inoue K, Ikeda K, Usui N, Adachi K, Okada Y (1984) Phase II study of 4′-O-tetrahydropyranyladriamycin (THP-ADM). Gan To Kagaku Ryoho 11:138–142
Ogawa M, Miyamoto H, Inagaki J, Horikoshi N, Ezaki K, Inoue K, Ikeda K, Usui N, Nakada H (1983) Phase I clinical trial of a new anthracycline, 4′-O-tetrahydropyranyladriamycin. Gan To Kagaku Ryoho 10:129–133
Tominaga T, Kitamura M, Hayashi K, Takahashi I, Kosaki G (1984) Effect of 4′epi-adriamycin, THP-adriamycin, and mitoxantron on patients with advanced and recurrent breast cancer. Gan To Kagaku Ryoho 11:1669–1674
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) 4′-O-Tetrahydropyranyladriamycin as a potent new antitumor agent. Cancer Res 42:1462–1467
Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Tatsuta K, Takeuchi T (1979) Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot, 32:1082–1084
Wakui A, Yokoyama M, Konno K, Nakai Y, Sakano T, Koyama Y, Imamura Y, Nakajima O, Nijima T, Akaza H, Kimura I, Ohnoshi T, Hiraki S, Kato T, Nishimura H, Umezu J, Saito T (1985) Phase I trial of 4′-O-tetrahydropyranyl-doxorubicin (THP), a multi-institutional cooperative study. Gan To Kagaku Ryoho 12:118–124
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miller, A.A., Scheulen, M.E., Kleeberg, U.R. et al. Phase I study of pirarubicin. J Cancer Res Clin Oncol 114, 91–94 (1988). https://doi.org/10.1007/BF00390491
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00390491